Fatal lactic acidosis associated with the use of combination oral medications to treat reactivation of hepatitis B

Stanley Martin Cohen, Ronald M. Levy, John F. Jovanovich, Joseph Ahn

Research output: Contribution to journalArticle

19 Scopus citations

Abstract

Oral nucleos(t)ide analogs for the treatment of hepatitis B virus (HBV) infection are well tolerated with minimal side effects. These agents do carry a Food and Drug Administration "black box" warning about the development of fatal lactic acidosis on the basis of data from the human immunodeficiency virus literature. However, no previously published cases of this lethal side effect have been reported in patients undergoing HBV treatment using the current Food and Drug Administration-approved HBV medications. We report a case of HBV reactivation after chemotherapy for leukemia, and the development of fatal lactic acidosis attributed to the use of combination oral HBV medications.

Original languageEnglish (US)
Pages (from-to)1008-1010
Number of pages3
JournalJournal of Clinical Gastroenterology
Volume43
Issue number10
DOIs
StatePublished - Nov 1 2009

Keywords

  • Chemotherapy-induced reactivation
  • Hepatitis B
  • Nucleoside analogs
  • Nucleotide analogs

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Fatal lactic acidosis associated with the use of combination oral medications to treat reactivation of hepatitis B'. Together they form a unique fingerprint.

  • Cite this